AtheroNova Inc. Form 8-K January 23, 2013

#### **UNITED STATES**

# SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 8-K

# CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: (Date of earliest event reported)

January 23, 2013

#### ATHERONOVA INC.

(Exact name of registrant as specified in charter)

#### Delaware

(State or other Jurisdiction of Incorporation or Organization)

000-52315 (Commission File Number)

20-1915083

(IRS Employer Identification No.)

2301 Dupont Drive, Suite 525 Irvine, CA 92612 (Address of Principal Executive Offices and zip code)

> (949) 476-1100 (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

[]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[]	Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
[]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Edgar Filing: AtheroNova Inc. - Form 8-K

Item 7.01. Regulation FD Disclosure.

On January 23, 2103, Thomas W. Gardner, the Registrant's Chief Executive Officer, will participate in the Noble Financial Capital Markets' Ninth Annual Equity Conference to be held in Hollywood, Florida. A copy of Mr. Gardner's presentation is being furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

The following exhibits are filed herewith:

Exhibit

Number Description

99.1 AtheroNova Inc. Investor Presentation.\*

<sup>\*</sup> Furnished, not filed.

# Edgar Filing: AtheroNova Inc. - Form 8-K

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AtheroNova Inc.

Date: January 23, 2013 By: /s/ Mark Selawski

Mark Selawski

Chief Financial Officer & Secretary

3